Abstract
A multicenter observational study of 2059 PCI patients compared the ultrathin-strut BDP-EES (Eternia) with the DP-EES (Xience) over 24 months. Patients in the Eternia group were older with more chronic total occlusions. MACE rates were 3.7 % (Xience) vs 3.8 % (Eternia; p = 0.939), with no significant differences in mortality, TVR, or stent thrombosis. No definite or probable stent thrombosis was reported in either group, and possible thrombosis rates were low (0.3 % vs 0.4 %). These findings suggest that biodegradable and durable polymer platforms offer similar long-term performance. The Eternia stents demonstrated equivalent safety and efficacy to Xience stents at 24 months.